Similarly, Vasohibin 2 (VASH2) protein suppresses pancreatic CSCs through decreasing SMO and Gli1/2 (Yang et al., 2020), while also functioning as a tumor promoter, stimulating resistance to doxorubicin (DOX) (Mirzaei et al., 2021) upregulating pancreatic CSCs via the Hh and Notch pathways (Liang et al., 2021a). This evidence concerns the gene VASH2 and neoplasm.